News PhRMA sues Trump administration over GLOBE rebate scheme PhRMA is challenging the Trump administration's GLOBE model for Most-Favoured Nation pricing in Medicare Part B in a US district court.
News GLOBE model finalised, with narrowed scope and fewer savings CMS has finalised a new drug pricing policy for Medicare that has drawn sharp criticism from the pharma industry.
Market Access What the revised 340B rebate pilot programme means for pharm... While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.
Market Access Policy in Focus: What’s new with CMS drug price negotiation,... Hogan Lovells partner Alice Valder Curran returned to elucidate some of the finer points of the latest communication from CMS.
News Medicare obesity drug pilot extended after insurer pushback Medicare will cover the cost of a pilot of weight-loss drug coverage, after health insurers refuse to take part.
News US court says pharma giants must face False Claims suit An appeals court in the US has said AbbVie, AstraZeneca, Novartis, and Sanofi must defend claims they defrauded federal and state governments.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.